ChiCTR2400095047 版本V1.0 版本创建时间2024/12/31 16:54:45 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400095047 

最近更新日期:

Date of Last Refreshed on:

2024-12-31 16:54:36 

注册时间:

Date of Registration:

2024-12-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

成人癫痫的专病队列研究

Public title:

Cohort Study on Adult Epilepsy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

成人癫痫的专病队列研究

Scientific title:

Cohort Study on Adult Epilepsy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴冬燕 

研究负责人:

吴冬燕 

Applicant:

Dongyan WU 

Study leader:

Dongyan Wu 

申请注册联系人电话:

Applicant telephone:

+86 13918751650

研究负责人电话:

Study leader's telephone:

+86 21 54602723

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

walkwinter@163.com

研究负责人电子邮件:

Study leader's E-mail:

5431@huashan.org.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市静安区乌鲁木齐中路12号

研究负责人通讯地址:

乌鲁木齐中路12号

Applicant address:

12th WulumuqiZhong Road, Shanghai 200040, China.

Study leader's address:

No.12 Middle Wulumuqi Road,Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

复旦大学附属华山医院

Applicant's institution:

Huashan Hospital, Fudan University

研究负责人所在单位:

复旦大学附属华山医院

Affiliation of the Leader:

Huashan Hospital, Fudan University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2024)临审第(1314)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

复旦大学附属华山医院伦理审查委员会

Name of the ethic committee:

Institutional Review Board Huashan Hospital Fudan University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-12-05 00:00:00

伦理委员会联系人:

全菁

Contact Name of the ethic committee:

Quan Jing

伦理委员会联系地址:

乌鲁木齐中路12号

Contact Address of the ethic committee:

No.12 Middle Wulumuqi Road,Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 52888921

伦理委员会联系人邮箱:

Contact email of the ethic committee:

quanjing1975@163.com

研究实施负责(组长)单位:

复旦大学附属华山医院

Primary sponsor:

Huashan Hospital, Fudan University

研究实施负责(组长)单位地址:

乌鲁木齐中路12号

Primary sponsor's address:

No.12 Middle Wulumuqi Road,Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华山医院

具体地址:

乌鲁木齐中路12号

Institution
hospital:

Huashan Hospital, Fudan University

Address:

No.12 Middle Wulumuqi Road,Shanghai

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

self-funded

Target disease:

Epilepsy is characterized by transient central nervous system dysfunction caused by abnormal, excessive neuronal discharges in the brain. It exhibits features of paroxysmal onset, recurrence, and spontaneous remission.

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

研究成人癫痫患者的临床特征、治疗状况及预后发展,主要研究目的为影响癫痫患者预后的主要因素,次要研究目的为不同癫痫分类的疾病特征,癫痫患者及家属对疾病的相关认知,不同治疗策略对生活质量及下一代健康结局的影响。  

Objectives of Study:

This study aims to investigate the clinical characteristics, treatment status, and prognosis of adult epilepsy patients. The primary objective is to identify key factors influencing patient prognosis. Secondary objectives include examining the disease characteristics of different epilepsy classifications, assessing patients’ and their families’ knowledge about epilepsy, and evaluating the impact of various treatment strategies on quality of life and health outcomes in the next generation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.符合2017年国际抗癫痫联盟颁布的癫痫分类诊疗标准;
2.性别不限,年龄在18-70周岁(含18周岁和70周岁);
3.对研究者的沟通可以有正常的理解和语言表达能力,能顺利完成量表内容者;

Inclusion criteria

1.Conforms to the epilepsy classification and diagnostic criteria established by the International League Against Epilepsy (ILAE) in 2017.
2.Participants of any gender, aged 18 to 70 years;
3.Participants who have adequate comprehension and verbal communication skills to interact effectively with the researchers and can complete the questionnaire assessments successfully.

排除标准:

1.存在血流动力学不稳定的情况(如急性冠状动脉综合征等需要紧急医疗处理的问题);
2.存在不稳定的精神疾病;
3.有酗酒及物质依赖史;

Exclusion criteria:

1.Presence of hemodynamic instability (e.g., acute coronary syndrome or other conditions requiring urgent medical intervention).
2.Presence of unstable psychiatric disorders.
3.History of alcohol abuse or substance dependence.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2036-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-01 00:00:00 To 2026-12-31 00:00:00  

干预措施:

Interventions:

组别:

癫痫组

样本量:

2650

Group:

Epilepsy Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

复旦大学附属华山医院 

单位级别:

三级甲等 

Institution
hospital:

Huashan Hospital, Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

癫痫完全缓解率

指标类型:

主要指标

Outcome:

Epilepsy Complete Remission Rate

Type:

Primary indicator

测量时间点:

每年随访时(至入组后第10年)

测量方法:

电话随访确认患者发作事件情况。

Measure time point of outcome:

At the annual follow-up (up to the 10th year after enrollment)

Measure method:

Follow-up to confirm the occurrence of seizure events in patients via phone.

指标中文名:

治疗有效率

指标类型:

主要指标

Outcome:

Treatment Efficacy Rate

Type:

Primary indicator

测量时间点:

在治疗第1年及第2年进行评估

测量方法:

电话随访确认患者发作事件情况。

Measure time point of outcome:

Assessment will be conducted at the 1st and 2nd year of treatment.

Measure method:

Follow-up to confirm the occurrence of seizure events in patients via phone.

指标中文名:

脑电痫样放电的缓解率

指标类型:

主要指标

Outcome:

The remission rate of electroencephalographic (EEG) epileptiform discharges

Type:

Primary indicator

测量时间点:

在治疗第1年及第2年进行评估

测量方法:

根据EEG记录

Measure time point of outcome:

Assessment will be conducted at the 1st and 2nd year of treatment.

Measure method:

Based on EEG recordings

指标中文名:

治疗不良反应发生率

指标类型:

次要指标

Outcome:

The incidence rate of treatment-related adverse reactions

Type:

Secondary indicator

测量时间点:

每年随访时(至入组后第10年)

测量方法:

电话随访询问患者不良反应,包括治疗不良反应,妊娠并发症,妊娠结局,子代结局。

Measure time point of outcome:

At the annual follow-up (up to the 10th year after enrollment)

Measure method:

Follow-up to inquire about adverse reactions via phone, including treatment adverse reactions, pregnancy complications, pregnancy outcomes and offspring outcomes.

指标中文名:

精神情绪

指标类型:

次要指标

Outcome:

Mental state

Type:

Secondary indicator

测量时间点:

每年随访时

测量方法:

汉密尔顿焦虑量表、汉密尔顿抑郁量表

Measure time point of outcome:

At the annual follow-up

Measure method:

Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale (HAM-D)

指标中文名:

睡眠质量

指标类型:

次要指标

Outcome:

sleep quality

Type:

Secondary indicator

测量时间点:

每年随访时

测量方法:

匹茨堡睡眠质量指数量表、失眠严重程度指数量表

Measure time point of outcome:

At the annual follow-up

Measure method:

Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI)

指标中文名:

日间功能状态

指标类型:

次要指标

Outcome:

Daytime functional status

Type:

Secondary indicator

测量时间点:

每年随访时

测量方法:

Chalder疲劳量表、Epworth嗜睡量表

Measure time point of outcome:

At the annual follow-up

Measure method:

Chalder Fatigue Scale, Epworth Sleepiness Scale (ESS)

指标中文名:

认知功能

指标类型:

次要指标

Outcome:

Cognitive function

Type:

Secondary indicator

测量时间点:

每年随访时

测量方法:

简易精神状态量表,蒙特利尔认知评估

Measure time point of outcome:

At the annual follow-up

Measure method:

Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA)

指标中文名:

疾病病耻感

指标类型:

次要指标

Outcome:

disease stigma

Type:

Secondary indicator

测量时间点:

入组时

测量方法:

癫痫患者病耻感评分量表

Measure time point of outcome:

baseline

Measure method:

Epilepsy Stigma Scale

指标中文名:

疾病相关认知

指标类型:

次要指标

Outcome:

Disease-related cognition

Type:

Secondary indicator

测量时间点:

入组时

测量方法:

癫痫的知识和态度调查表

Measure time point of outcome:

baseline

Measure method:

Epilepsy Knowledge and Attitude Questionnaire

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

若发表文献,以期刊要求共享数据。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

If the literature is published, data should be shared in accordance with the journal's requirements.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

基于华山医院Redcap完成数据采集及管理工作。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management will be carried out based on the Redcap system at Huashan Hospital.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2024-12-31 16:54:36